Cerebras Systems (CBRS) has an average rating of buy and mean price target of $299.30, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $187.45, Change: $-39.27, Percent Change: -17.32%
Cerebras Systems (CBRS) reported a Q1 net loss late Tuesday of $0.22 per diluted share, narrowing from the loss of $0.46 a year earlier.Analysts polled by FactSet expected a loss of $0.16.Revenue in the three months ended March 31 rose to $193.4 million from $99.5 million a year earlier.Analysts expected $181.2 million.The company expects Q2 non-GAAP revenue of about $194 million. Analysts project $177.7 million.Cerebras expects full-year non-GAAP revenue of $855 million to $865 million. Analysts forecast $828 million.Cerebras shares fell 7.6% in after-hours trading.
Top cryptocurrencies fell Tuesday, with Bitcoin (BTC-USD) dropping below the $63,000 level.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, fell almost 3.5% in the past 24 hours. The Nasdaq 100 fell 3.2%, the S&P 500 decreased 1.3%, and the Dow Jones Industrial Average was down 0.1%.Bitcoin dropped 3.2% to $62,259, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume rose 9.5% to $29.78 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, declined 4.3% to $1,657.XRP (XRP-USD) dropped 2.7%, BNB (BNB-USD) fell 2.7%, and Solana (SOL-USD) lost 5.3%. Dogecoin (DOGE-USD) declined 5.1%, and Cardano (ADA-USD) shed 5.5%.The US 10-year Treasury yield stood at 4.509% at 3 p.m. ET Tuesday, up from 4.493% Monday, while the five-year yield rose to 4.288% from 4.261%.The total market value of the cryptocurrency industry fell 2.9% in the past 24 hours to $2.14 trillion, with trading volume rising 0.5% to $72.42 billion.Price: $62270.80, Change: $-1680.71, Percent Change: -2.63%
Cosmos Health (COSM) said Tuesday its pharmaceutical distribution subsidiary CosmoFarm will deploy an artificial intelligence-powered call center to support customer communications, order intake and routine support functions.The platform will include multilingual voice assistance, intelligent call routing, outbound campaign automation, back-end system integration and real-time reporting capabilities, the company said.